Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

Jan 15 (Reuters) - Zai Lab Ltd  9688.HK :
    * ZAI LAB ANNOUNCES POSITIVE TOPLINE RESULTS FOR TIVDAK IN
THE
CHINA SUBPOPULATION OF THE GLOBAL PHASE 3 INNOVATV 301 TRIAL IN
PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER
    * ZAI LAB LTD - TO SUBMIT NDA FOR TIVDAK TO NMPA IN Q1 2025
    * ZAI LAB LTD - TIVDAK IMPROVES OS, PFS, AND ORR IN CHINA
SUBPOPULATION
    * ZAI LAB LTD - TIVDAK SHOWS 45% REDUCTION IN RISK OF DEATH
IN
CHINA
    * ZAI LAB LTD: SAFETY PROFILE OF TIVDAK AMONG CHINA
SUBPOPULATION
WAS MANAGEABLE AND CONSISTENT WITH THAT OBSERVED IN GLOBAL
POPULATIO
    * ZAI LAB LTD - MEDIAN OS FOR TIVDAK NOT REACHED VERSUS
CHEMOTHERAPY 10.7 MONTHS

Source text:  ID:nBw7NBT8ca 
Further company coverage:  9688.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Zai Lab

See all news